Saturday, December 4, 2021
-Advertisement-

Tag: OTCQB:TBPMF

Tetra Bio-Pharma enters into agreement with Dr. Louis-Philippe de Lorimier

Tetra Bio-Pharma announced that it has added international expert Dr. Louis-Philippe de Lorimier, a board certified veterinary oncologist, to its clinical advisory board for the veterinary market. "We are leveraging our current R&D work in humans to accelerate the development of the first cannabinoid-based drug for pets in the cancer-associated supportive therapy market, including pain," said states Dr. Guy Chamberland, Chief Scientific Officer (CSO) of Tetra. "This market is underserved and patients and their owner are waiting for alternatives that are safer, more tolerable and more efficacious. We believe that our collaboration with Dr. de Lorimier will bring significant contributions to the launch of the first Health Canada approved drug for pets using cannabinoid-based active ingredients," he added. Once approved, the trial will be run at private veterinary clinics across Canada, which treats tens of thousands of animals every year. Cancer is the leading cause of death in pets, affecting 50% of dogs above age 8, and 40% of cats above 10 years of age. Tetra is developing cannabis-based products for the treatment of acute and chronic conditions that affect domestic animals, including cats, dogs and horses. The company is going to use its pharmaceutical formulation and drug development expertise to bring...
-Advertisement-Digital Senate